Yimitasvir clinical trials
Also written DAG181.
How each study uses yimitasvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Sunshine Lake Pharma Co., Ltd. (5) · Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses yimitasvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy SubjectsCompletedPhase 1Sunshine Lake Pharma Co., Ltd.NCT04552808Written as Yimitasvir Phosphate
- Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRDCompletedPhase 1Sunshine Lake Pharma Co., Ltd.NCT04565171Written as Yimitasvir Phosphate Capsule
- A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I PatientsCompletedPhase 3Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.NCT04155515Written as DAG181
- Phase 2 Study of Yimitasvir Phosphate CapsulesCompletedPhase 2Sunshine Lake Pharma Co., Ltd.NCT03458481Written as DAG181
- Phase 3 Study of Yimitasvir Phosphate CapsulesCompletedPhase 3Sunshine Lake Pharma Co., Ltd.NCT03487107Written as DAG181
- To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese VolunteersCompletedPhase 1Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.NCT03610880Written as TG-2349 (400 mg) plus DAG181 (200 mg)
- The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults SubjectsCompletedPhase 1Sunshine Lake Pharma Co., Ltd.NCT03462173Written as yimitasvir
Codes
What other systems call yimitasvir · ClinicalTrials.gg INT000998
- MeSH (NLM) C000628665yimitasvirOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000628665 | yimitasvir | One source ClinicalTrials.gov |
Also registered as yimitasvir phosphate (UNII 7HJK69JC34).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.